T-cell receptor recognition of peptide–MHC class I complexes (TCR-pMHC Interaction)

T-cell receptor (TCR) recognition of peptide–MHC class I (pMHC) complexes is a fundamental immunological process where CD8+ cytotoxic T lymphocytes identify specific antigenic peptides presented by Major Histocompatibility Complex (MHC) molecules. In the context of DC–tumor fusion cells, dendritic cells are fused with tumor cells to create a hybrid antigen-presenting cell that expresses both the costimulatory machinery of the DC and the full spectrum of tumor-associated antigens. This interaction is designed to overcome tumor immune evasion by providing a potent stimulus for the expansion of tumor-specific T cells. The TCR binds to the pMHC complex, triggering a signaling cascade that leads to T-cell proliferation and the targeted destruction of tumor cells expressing the same antigen. This mechanism is a central focus of cancer vaccine development and cellular immunotherapies aimed at enhancing the precision and strength of the anti-tumor immune response.

Other names

TCR-pMHC recognitionAntigen-specific T-cell activationDC-tumor fusion cell signalingMHC-I restricted antigen presentation

Activation of antigen-specific CD8+ T cells through the binding of T-cell receptors to tumor-derived peptides presented on MHC class I molecules, often enhanced by costimulatory signals provided by dendritic cell components.